Payment overview · 2025
General Payments
$27.60
2 reported records · 2 companies
Healthcare provider profile · identity verified
Jay Jackson, MD
Allopathic & Osteopathic Physicians|Family Medicine · JUNCTION, TX · NPI 1760863138
Verified facts
What the public records show
CMS Open Payments records show Jay Jackson, MD received $27.60 in general payments during 2025 across 2 reported records.
AstraZeneca Pharmaceuticals LP accounted for 50.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.91 | 50.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.69 | 49.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $27.60 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 317 | 74 |
| Atorvastatin Calcium | Atorvastatin Calcium | 314 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 250 | 74 |
| Lisinopril | Lisinopril | 222 | 60 |
| Gabapentin | Gabapentin | 209 | 54 |
| Potassium Chloride | Potassium Chloride | 182 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 174 | 42 |
| Losartan Potassium | Losartan Potassium | 165 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 164 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 160 | 47 |
| Furosemide | Furosemide | 158 | 47 |
| Ozempic | Semaglutide | 135 | 24 |
| Metformin Hcl | Metformin Hcl | 112 | 39 |
| Omeprazole | Omeprazole | 112 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 110 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 99 | 33 |
| Meloxicam | Meloxicam | 91 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 87 | 15 |
| Allopurinol | Allopurinol | 84 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 18 |
| Famotidine | Famotidine | 77 | 14 |
| Montelukast Sodium | Montelukast Sodium | 72 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 13 |
| Divalproex Sodium | Divalproex Sodium | 61 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 61 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 14 |
| Fentanyl | Fentanyl | 59 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 57 | 17 |
| Carvedilol | Carvedilol | 56 | 13 |
| Pregabalin | Pregabalin | 55 | 11 |
| Simvastatin | Simvastatin | 55 | 14 |
| Donepezil Hcl | Donepezil Hcl | 53 | suppressed |
| Mirtazapine | Mirtazapine | 53 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 14 |
| Xarelto | Rivaroxaban | 52 | suppressed |
| Memantine Hcl | Memantine Hcl | 51 | suppressed |
| Prednisone | Prednisone | 51 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 13 |
| Sertraline Hcl | Sertraline Hcl | 48 | 12 |
| Finasteride | Finasteride | 46 | 11 |
| Jardiance | Empagliflozin | 45 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 44 | 11 |
| Spironolactone | Spironolactone | 43 | 12 |
| Metformin Hcl Er | Metformin Hcl | 42 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 13 |
| Nifedipine Er | Nifedipine | 39 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 11 |
| Terazosin Hcl | Terazosin Hcl | 34 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 34 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Cephalexin | Cephalexin | 31 | 20 |
| Eliquis | Apixaban | 31 | 13 |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Alprazolam | Alprazolam | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Lactulose | Lactulose | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 21 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Cefdinir | Cefdinir | 19 | 15 |
| Estradiol | Estradiol | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Azithromycin | Azithromycin | 17 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $27.60 · 2 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, The Cologuard Plus Collection Kit | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error